Active, Not Recruiting
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
NCT03731260
- Conditions
- Immune System Diseases, Indolent Systemic Mastocytosis, Mast Cell Activation Disorders, +6 more
- Locations
-
- University of Alabama at Birmingham Birmingham, Alabama, United States
- Mayo Clinic Hospital Phoenix, Arizona, United States
- Stanford Cancer Institute Stanford, California, United States
- Mayo Clinic Florida Jacksonville, Florida, United States